Menu
The Goodman Institute Health Blog
  • Home
  • Authors
    • Devon Herrick, Ph.D.
    • John C. Goodman
  • Popular Topics
    • Artificial Intelligence and Healthcare
    • Consumer-Driven Health Care
      • Affordable Care Act
      • Cost of Healthcare
      • COVID-19 and Public Health
      • Doctors & Hospitals
      • Public Insurance
      • Policy & Legislation
    • Direct Primary Care
    • Health Economics & Costs
      • Drug Prices & Regulations
      • Health Insurance
      • Health Reform
    • Medical Tourism
    • Telemedicine
    • Medicare
      • Single-Payer/Medicare-for-All
  • Goodman Institute
  • Contact
The Goodman Institute Health Blog

Thursday Links

Posted on March 30, 2023 by John C. Goodman

Rep. Earl L. “Buddy” Carter (R-GA) leads a bipartisan group of House members who want to bring drug production onshore.

Warren piles on — attacking MA plans. Private insurers have a “long history of exploiting the government out of billions of dollars,” she says.

Against the “AI pause.”

Yglesias: The problem with the media is the audience.

Does Medicaid expansion reduce employment?

2 thoughts on “Thursday Links”

  1. Bart Ingles says:
    March 30, 2023 at 12:32 pm

    Is it Medicaid expansion itself reducing employment (i.e. reducing the need to seek employer-sponsored insurance), or is it the associated tax/benefit cliffs and tax bubbles? We see the same with Obamacare, Medicare (IRMAA), the Social Security tax torpedo, and surely other programs as well. It’s hard to believe anything so irrational could be deliberate, but they shouldn’t have been difficult to mitigate had there been the desire to do so.

    Loading...
    Reply
  2. Devon Herrick says:
    March 30, 2023 at 4:48 pm

    Drugs made domestically: On the one hand the FDA can inspect more often and more easily if drugs are made in the U.S. On the other hand, drugs made abroad can be stopped from entering the drug supply chain more easily with import detention. The problem is the FDA does not inspect foreign firms often enough and the FDA investigators do not have the power to crack down on violators. The latter is because Congress comes to the rescue when drug companies complain about the FDA shutting down their production lines.

    Loading...
    Reply

Join the conversation.Cancel reply

For many years, our health care blog was the only free enterprise health policy blog on the internet. Then, when the NCPA closed its doors, the health blog stopped as well.

During this five-year hiatus no one else has come forward to claim the space. So, my colleagues and I have decided to restart the blog in connection with the Goodman Institute. We invite you and others to use this forum to share your views.

John C. Goodman,

Visit www.goodmaninstitute.org

Subscribe via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 36 other subscribers

Popular Topics

©2025 The Goodman Institute Health Blog | Website by Lexicom
%d